STOCKS TELEGRAPH

Tag: MSA

  • Alterity Therapeutics Ltd. (ATHE) Stock Surges as Scope of Patent is Explored in Treatment of Alzheimer’s and Parkinson’s

    Alterity Therapeutics Ltd. (ATHE) stock prices were down by 2.11%, bringing the price per share down to USD$1.39 at the end of the trading day. Subsequent premarket fluctuations saw the stock surge by 30.22%, bringing it up to USD$1.81.

    USPTO Patent

    July 1st, 2021 saw the company announce that it had been granted a new composition of matter patent by the United States Patent and Trademark Office (USPTO). This patent will offer the company a vast monopoly over a new class of iron chaperons, which is a technology capable of redistributing excess iron in the central nervous system. The structural backbone presented in the patent serves as the foundation for small molecule drug candidates that have the capacity to cross the blood brain barrier, thus directly attacking sources of various neuropathologies.

    Scope of Patent

    Alzheimer’s and Parkinson’s are associated with excess levels of iron in the brain, as are various other important neurodegenerative diseases. Titled “Compounds for and Methods of Treating Diseases”, the patent was granted following an expedited review by the USPTO. It includes coverage of more than 150 novel pharmaceutical compositions that are designed to facilitate the redistribution of the labile iron that is involved in a myriad of neurodegenerative conditions.

    Dissecting the Patent

    The company is set to launch the Phase 2 trial of ATH434, its lead clinical candidate, by the end of the 2021 year. The small molecule drug is being developed for Multiple System Atrophy (MSA), which is a form of atypical parkinsonism where iron is essential in pathogenesis by promoting α-synuclein aggregation. Results from the Phase 2 study, in conjunction with the ongoing scientific investigation of the treatment, will facilitate the development and optimization of novel compounds that are expected to emerge from the new patent

    Continued Expansion

    The significant milestone represents an important part of our corporate strategy aimed to expand the company’s portfolio of potential disease modifying treatments for the demographic affected by neurodegenerative diseases. The newly covered compounds are designed to target excess brain iron resulting from the conditions, with the company hoping to identify a new clinical candidate by the time the lead clinical program results are reported.

    Future Outlook for ATHE

    Armed with the lucrative potential afforded by the granting of the patent, ATHE is poised to capitalize on the continued development of its lead product. The company is keen to continue its trajectory of success as it continues to explore added opportunities arising from the patent. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to usher in significant and sustained increases in shareholder value.

  • Alterity Therapeutics Ltd. (ATHE) Stock Skyrockets as Meme Stock Phenomenon Continues to Proliferate Stock Exchange

    Alterity Therapeutics Ltd. (ATHE) stock prices were down by 1.52% as of the market closing on June 30th 2021, bringing the price per share down to USD$1.30 at the end of the trading day. Subsequent pre-market fluctuations saw the stock skyrocket by a massive 66.92%, bringing it up to USD$2.17.

    EMA Guidance

    June 23rd, 2021 saw the company announce guidance it had received from the European Medicines Agency (EMA) in regard to key aspects of ATHE’s Phase 2 clinical trial for the treatment of Multiple System Atrophy (MSA) with its investigational drug ATH434. The company is actively preparing for the impending launch of the Phase 2 trial, which is scheduled to commence in the second half of 2021.

    About the EMA

    The EMA is an agency with jurisdiction in the European Union, with the responsibility of evaluating and supervising medicinal products. The agency plays a crucial role in the timely support of the sound development of high-quality, effective, and safe medicines for the treatment of respective patients. With their advice not being binding, the EMA influences improved trial designs to facilitate more robust and complete data in the evaluation of treatments.

    Scope of ATH434

    With MSA affecting a sizeable portion of the U.S population and the absence of any approved treatments for MSA, the scope of ATH434 is extensive. There is no regulatory precedence for defining clinical endpoints or guiding patient enrollment, thus requiring greater consideration in developing a trial design that is most suitable. Accordingly, the company has recruited clinical experts and global regulatory authorities for input. ATHE is also conducting BioMUSE, a natural history study designed to identify biomarkers and clinical endpoints most appropriate to capture efficacy signals in the Phase 2 study.

    Meme Stock Phenomenon

    Despite the promising development of the course of the ATH434 trial, the recent surge in ATHE’s stock price seems unmerited. Such drastic movement in the absence of news coverage or changes in fundamentals likely signals the company having been the latest target of the meme stock phenomenon that has resurged in the stock market. Driven by Reddit-based retail investors, underperforming companies with high short interest are selected for a coordinated short squeeze.

    Future Outlook for ATHE

    Armed with the recent surge in its equity value, ATHE finds itself with a fortuitous influx of resources to leverage in order to ensure more organic growth. Investors are hopeful that the company will manage to use the resources at its disposal to continue its trajectory of success.

  • Plus Therapeutics, Inc. (PSTV) stock is high today. What’s going on?

    Plus Therapeutics, Inc. (PSTV) stock is high today. What’s going on?

    Plus Therapeutics, Inc. (PSTV) entered into the Master Services Agreement(MSA) with Piramal Pharma Solutions(PPS) today after which the PSTV stock price saw an uptrend of  45.26% to reach $3.98 a share as of this writing. Plus Therapeutics gained 3.40% at the previous closing and its per-share price was $2.74. Let’s see what the agreement says.

    MSA with Piramal Pharma Solutions (PPS).

    Plus Therapeutics, Inc. (PSTV) is a clinical-stage pharmaceutical company mainly focused on the treatment of cancer diseases. PSTV today announced its Master Services agreement with Piramal Pharma Solutions (PPS), leading contract development and manufacturing firm, to develop, manufacture, and supply Rhenium NanoLiposome (RNL™) which is an intermediate drug product of PSTV. According to this agreement, PSTV will transfer and perform its analytical methods at PPS’s drug product facility in Lexington, Kentucky along with the development of microbiological methods, intermediate drug manufacturing, and stability studies.

    Future Impact of MSA

    Plus Therapeutics is focused on the advancement of Rhenium NanoLiposome to make it a novel treatment for patients who are suffering glioblastoma, aggressive cancer often occurs in the brain or spinal cord.Plus management thinks that agreement with PPS will fast the process of RNL development and its regulatory approval in the future.

    Financial Overview of PSTV

    On February 22, 2021, PSTV announced its fourth quarter and fiscal year 2020 results according to which PSTV had an $8.3 million amount on hand as of December 30, 2021, as compared to a $17.6 million cash balance in 2019.Operating expenses in 2020 surged to $8.4 million from $5.9 million in 2019.PSTV net loss dropped to $8.2 million in 2020 while it was $11.4 million in the prior year.

    Conclusion:

    Investors are responding to PSTV stock after its master services agreement with PPS for the speedy development of RNL.Plus is expected to complete many clinical trials of its pipeline products in the upcoming quarters.Increase in operating expenses in 2020 suggests that PSTV stock is growing with time.Hence investors having long-term prospects need to keep an eye on it.